BPC-157 and Vascular Health: What the Research Actually Shows

What the vascular research on BPC-157 shows, where it stops, and what is still unknown about safety.

Research on BPC-157 and blood vessels comes almost entirely from animal and cell studies (McGuire et al., 2025). In that work it relaxed rat arteries through nitric oxide, increased new vessel growth, and sped the return of blood flow after an artery was blocked in rats (Hsieh et al., 2020, Hsieh et al., 2017). The three published human pilot studies looked at knee pain, interstitial cystitis, and intravenous safety (McGuire et al., 2025).

Maybe a recent scan said your arteries are older than you are, and your doctor offered a statin and "see you next year." Or someone your age had a heart attack, and now you are reading about peptides late at night. A heart worry like yours calls for a real workup with a physician who reads your labs and your arteries.

BPC-157 is a 15-amino-acid fragment of a protein found in human gastric juice (Chang et al., 2011). It lacks FDA approval and is banned in professional sports, and clinicians and athletes use it more and more (Vasireddi et al., HSS J 2025). A 2025 systematic review found 35 preclinical studies and a single clinical study (Vasireddi et al., HSS J 2025).

Why Do Researchers Study BPC-157 Where Blood Supply Is Poor?

Tendons and the junctions where tendon meets muscle have a poor blood supply (McGuire et al., 2025). Reviewers describe BPC-157's preclinical effects on new vessel growth and repair as most notable in those tissues (McGuire et al., 2025).

How Does BPC-157 Work? The Science Explained

Researchers first studied BPC-157 for protecting the stomach lining, as part of the cytoprotection research of the early 1990s (Sikiric et al., 2022). Later work extended to blood vessels (Seiwerth et al., 2014).

1. It Relaxed Blood Vessels in Rat Studies

In isolated rat aorta, BPC-157 widened the vessel in a concentration-dependent way (Hsieh et al., 2020). The effect weakened when the vessel lining (the endothelium) was removed, and drugs that block nitric oxide inhibited it (Hsieh et al., 2020). The authors traced the effect to the Src-Caveolin-1-eNOS signaling pathway (Hsieh et al., Scientific Reports 2020).

In the lab, BPC-157 led vessel cells to make nitric oxide (NO), and the vessel relaxing effect depended on nitric oxide (Hsieh et al., 2020). This was a rat artery in a dish, so it tells us nothing yet about blood pressure in people.

2. It Increased New Blood Vessel Growth in Animal Models

A 2014 review by researchers at the University of Zagreb called BPC 157 "the most potent angiomodulatory agent," acting through nitric oxide, VEGF (vascular endothelial growth factor), and FAK pathways (Seiwerth et al., Current Pharmaceutical Design 2014).

In rats with a blocked hind-limb artery, BPC-157 sped the recovery of blood flow and raised the number of vessels in the muscle (Hsieh et al., 2017). In human vascular endothelial cells, it raised levels of VEGFR2, a receptor that drives new vessel growth (Hsieh et al., J Mol Med 2017).

3. It Helped Tendon Cells Move and Survive in Lab Studies

In cells from rat Achilles tendons, BPC-157 sped outgrowth from tendon explants, improved cell survival under oxidative stress, and increased cell migration through the FAK-paxillin pathway. It did not directly increase how fast the cells multiplied (Chang et al., Journal of Applied Physiology 2011).

Can BPC-157 Help With Blocked Vessels?

A 2022 review from the same Zagreb group summarized animal work in which BPC-157 counteracted syndromes caused by blocked major vessels, including ischemia-reperfusion injury after the Pringle maneuver and Budd-Chiari syndrome. The proposed mechanism is the recruitment of collateral vessels that restore flow around the blockage (Sikiric et al., World Journal of Gastroenterology 2022).

These were animal models (Sikiric et al., 2022). The three published human pilot studies of BPC-157 looked at knee pain, interstitial cystitis, and intravenous safety (McGuire et al., 2025).

Is BPC-157 Safe? What You Need to Know

Its safety in people is unknown (Vasireddi et al., 2025). The 2025 systematic review found preclinical safety studies with no adverse effects across several organ systems, and no clinical safety data (Vasireddi et al., 2025).

Animal toxicity data. In toxicity studies in mice, rats, rabbits, and dogs, BPC-157 was well tolerated and showed no genetic or embryo-fetal toxicity. Dogs given 2 mg/kg had a drop in creatinine that resolved two weeks after the drug was stopped (Xu et al., Regulatory Toxicology and Pharmacology 2020).

Human data. The only published intravenous study gave BPC-157 to two adults. It reported no side effects and no change in the heart, liver, kidney, thyroid, or blood sugar markers it tested, and the authors called for more studies to confirm safety (Lee and Burgess, Altern Ther Health Med 2025). Rigorous, large-scale trials are lacking (McGuire et al., 2025).

The cancer question. BPC-157 raised VEGFR2 in rat muscle and in human endothelial cells (Hsieh et al., 2017). Some cancer cells make VEGFR2 in large amounts, and the cancer drug ramucirumab works by blocking VEGFR2, which may prevent the new blood vessels tumors need to grow (National Cancer Institute).

Product quality and regulation. Adverse effects are possible from unregulated manufacturing and contamination (Vasireddi et al., 2025). The FDA previously placed BPC-157 in category 2, its list of bulk drug substances for compounding that may present significant safety risks, and the nomination was later withdrawn (FDA). The FDA page still lists its concerns: possible immune reactions for some routes, impurity concerns, and limited safety information (FDA). It says the agency lacks enough information to know whether the drug would cause harm in people (FDA).

How Does BPC-157 Compare to Other Peptides Like TB-500 and Ipamorelin?

Feature	BPC-157	TB-500	Ipamorelin
What it is	A 15-amino-acid fragment of a gastric juice protein	A fragment of thymosin beta-4 (LKKTETQ)	A selective growth hormone secretagogue
Human data	Three small pilot studies	FDA identified no human exposure data	FDA cites a published study with serious adverse events, including death, after intravenous use for gastric motility
FDA compounding list	Previously in category 2 (may present significant safety risks), nomination withdrawn	Previously in category 2, nomination withdrawn	In category 2 for outsourcing facilities (503B) since September 29, 2023

Sources: Chang et al., 2011, McGuire et al., 2025, Raun et al., Eur J Endocrinol 1998, FDA.

What Has BPC-157 Been Studied For?

Preclinical studies report effects in:

Muscle, tendon, ligament, and bone injuries in animal models (Vasireddi et al., 2025)
The stomach lining and gut, where the research began (Sikiric et al., 2022)
Blocked vessels and reduced blood flow in animal models (Sikiric et al., 2022, Hsieh et al., 2017)

In people, the published work is three small pilot studies (McGuire et al., 2025). BPC-157 should be treated as investigational until well-designed clinical trials are done (McGuire et al., 2025).

Frequently Asked Questions

What are BPC-157's effects on the heart?

One published pilot study gave BPC-157 intravenously to two adults and found no measurable effect on the heart markers it tested. The vascular findings come from animal and cell work: rat aorta relaxing through nitric oxide, and faster blood flow recovery after a blocked leg artery in rats.

Is BPC-157 good for heart health?

There is no human evidence that it is. The three published human pilot studies looked at knee pain, interstitial cystitis, and intravenous safety.

Does BPC-157 lower blood pressure?

No published human study has tested whether BPC-157 lowers blood pressure. The vessel-relaxing effect was seen in isolated rat aorta in a lab. Talk with your clinician about treating high blood pressure.

Can BPC-157 help venous insufficiency?

It has not been studied in people with venous insufficiency. Animal studies of blocked major vessels, including Budd-Chiari syndrome models, reported that BPC-157 recruited collateral vessels to restore blood flow.

Is BPC-157 FDA-approved?

No. BPC-157 lacks FDA approval and is banned in professional sports. The FDA also lists safety concerns about compounded BPC-157, including possible immune reactions and limited safety information.

The bottom line: BPC-157 has plausible vascular mechanisms in animal and cell studies, and almost no human data (McGuire et al., 2025). It is investigational, and the open safety questions, including the cancer question, deserve serious weight.

This content is for educational purposes only and does not constitute medical advice. BPC-157 is not FDA-approved for any condition. Consult with a qualified healthcare provider before starting any new treatment protocol.

References

Hsieh MJ, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020, 10:17078. PMID: 33051481
Seiwerth S, et al. BPC 157 and blood vessels. Curr Pharm Des. 2014, 20(7):1121-1135. PMID: 23782145
Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011, 110(3):774-780. PMID: 21030672
Sikiric P, et al. Cytoprotective gastric pentadecapeptide BPC 157 resolves major vessel occlusion disturbances, ischemia-reperfusion injury following Pringle maneuver, and Budd-Chiari syndrome. World J Gastroenterol. 2022, 28(1):23-46. PMID: 35125818
Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017, 95(3):323-333. PMID: 27847966
Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025, 21(4):485-495. PMID: 40756949
McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025, 18(12):611-619. PMID: 40789979
Xu C, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020, 114:104665. PMID: 32334036
Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025, 31(5):20-24. PMID: 40131143
Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998, 139(5):552-561. PMID: 9849822
US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026). fda.gov
National Cancer Institute. Ramucirumab. cancer.gov

Related Articles: